Monte Rosa Therapeutics (GLUE) and The Competition Head-To-Head Analysis

Monte Rosa Therapeutics (NASDAQ:GLUE) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Monte Rosa Therapeutics to similar companies based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.

Volatility and Risk

Monte Rosa Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics’ rivals have a beta of -1.86, meaning that their average share price is 286% less volatile than the S&P 500.

Earnings and Valuation

This table compares Monte Rosa Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67 million	-$38.63 million	-6.69
Monte Rosa Therapeutics Competitors	$713.66 million	$10.27 million	-18.80

Monte Rosa Therapeutics’ rivals have higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Monte Rosa Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-186.24%	-30.14%	-20.35%
Monte Rosa Therapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Analyst Recommendations

This is a breakdown of current recommendations for Monte Rosa Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	2	8	1	2.75
Monte Rosa Therapeutics Competitors	9903	15307	45655	1601	2.54

Monte Rosa Therapeutics presently has a consensus target price of $26.44, indicating a potential upside of 182.22%. As a group, “Biotechnology” companies have a potential upside of 126.22%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than its rivals.

Insider & Institutional Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Monte Rosa Therapeutics beats its rivals on 10 of the 13 factors compared.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.